Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (2091)	3/31/2017 3:49:08 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3559

<Variable rebates according to indication will become a common practice, IMO (unless the US has moved to a single-payer healthcare system).> Somehow, I do not share you view on "variable rebate". So, for cancer drug, for each indication we can expect variable rebate? On a separate note, Le-Trait facility AGAIN received FDA 483 observation note during February inspection: fdazilla.com One can speculate that this time observations were related in general toward operation of the facility, and less toward drug-specific Fill-Finnish operations!!!??? Be on "alert note"...drug shortage????